



EVALUATION OF PREGNANT WOMEN ANTIMALARIAL INTERMITTENT PRESUMPTIVE TREATMENT AND PREVALENCE OF SULFADOXINE-PYRIMETHAMINE RESISTANCE MARKERS IN FOUGAMOU, A GABONESE RURAL AREA



Fleuramie MIREMBOU BOUKOUMBA^{1,2}, Nancy Diamela MOUKODOUM¹, Pierre Blaise MATSIEGUI², Jean Bernard LEKANA-DOUKI^{1,3}



ABSTRACT:

Pregnant malaria remains one of complex forms of malaria. Despite the adoption of intermittent preventive treatment with Sulfadoxine-Pyrimethamine (IPT-SP), SP resistance emerged and haplotypes of *P. falciparum Dihydropteorate synthase (PfDHPS)* and *P. falciparum Dydrofolate reductase (PfDHFR)* associated with resistance increased.

Retrospective and cross sectional survey were done to investigate the IPT adhesion. Malaria was diagnosed using rapid diagnostic test and *PfDHFR* and *PfDHPS* were genotyped using PCR-RFLP.

We included 427 women at the time of delivery. The rate of adhesion to IPT-SP was 94.37% (n=403). For pregnant women including during cross sectional survey, only 8.7% (n=14) were infected with plasmodium.. The prevalence of triples mutations of *PfDHFR* VIRNI and AIRNI were 12.07% and 84.48% respectively. An undescribed profile of genotype 59 of *PfDHFR* was reported. The prevalence of mutant haplotypes of *PfDHPS* were SGEA, SGKA and AGEA was 37.93%, 25.86% and 12.07% respectively.

Data call for clinical trials to investigate the efficacy of ITP-SP.

INTRODUCTION

Despite upgrade of malaria fight, pregnant associated (PAM) malaria remains one of complex forms of malaria. PAM induces severe consequences for mother and newborn. So, several African countries adopted Intermittent Presumptive Treatment with Sulfadoxine Pyrimethamine (IPT-SP) to roll back PAM. But, some data reported highest level of markers of SP resistance in Africa: Haplotypes *PfDHFR*-(16- 51-59-108-164) VIRNI and AIRNI and SGEA, SGKA and AGEA of *PfDHPS*.

In Gabon, decrease of PAM burden were reported in urban areas, after implementation of IPT-SP. Nothing is known about pregnant women IPT-SP adhesion and prevalence of SP resistance markers in rural areas.

MATERIAL AND METHODS

Study site: Health Center of Fougamou (HCF)

Study population and inclusion criteria

Pop1: Pregnant women and after labour

- Delivery at HCF
- Seeing in antenatal consultation at HCF

Pop2: febrile patients

- Fever ($T^{\circ} \geq 37,5^{\circ}C$)
- Fever story during lasted 48H before consultation



Statistical analysis: Epi Info software

RESULTS

I. IPT-SP Adhesion level of pregnant women at the delivery Among 427 women who delivered at HCF 403 (94.4%) took IPT-SP during pregnancy. The distribution of the number of taking doses is showing in table 1.

Table 1: DISTRIBUTION OF WOMEN ACCORDING TO THE NUMBER OF TAKING DOSES

Number of taking Doses	1	2	3	ND
Women	65 (16.12%)	119 (29.52%)	193 (47.89%)	26 (6.45%)

The socio-demographical parameters of these included women correspond to the rural area: 74.53% without work and 47.2% live in villages around Fougamou.

II. IPT-SP and pregnant malaria

During the cross sectional study, 161 pregnant women were included. The prevalence of malaria was 8.7% (n=14). A positive impact of IPT-SP was observed. The prevalence of malaria was higher in women with parity ≤ 1 (17.65%) than those with parity ≥ 2 (2.15%), $p=0.001$. (Table 2).

Table 2: DISTRIBUTION OF MALARIA ACCORDING TO THE PARITY

Parity	0	1	2	3	≥ 5
numbers	36	32	30	26	18
<i>P. falciparum</i> infected women (%)	3 (8,33)	9 (28,12)	0 (0)	1 (3,85)	1 (5,55)
		17.65%			2.7%

Data showed that antimalarial prevention measures were highly followed: 80.2 % (n=129) slept under bed net, 66.45% (n=107) received information and education on malaria basis

III. Malaria in all febrile patients

We investigated malaria in all febrile consulted patients at HCF. We included 101 patients. The malaria prevalence was 60.4% (n=61) with a mean of parasitemia of $52,374 \pm 81,151$ Pf/ μ L. In this context, malaria affected blood cell level (Table 3). TABLE 3: COMPARISON OF BLOOD CELLS LEVELS ACCORDING MALARIA

Blood cells	Mean \pm SD		
	Plasmodium +	Plasmodium -	p-value
White cells $\cdot 10^3 / mm^3$	8.13 \pm 4.22	8.25 \pm 5.49	0.85
Red blood $10^6 / mm^3$	4.03 \pm 0.78	4.46 \pm 0.67	0.003
Haemoglobin (g/dl)	9.61 \pm 1.71	11.18 \pm 1.96	0.0001
Platelet. $10^3 / mm^3$	121.76 \pm 73.32	190.99 \pm 125.53	0.002

IV. High level of molecular markers of SP resistance

TABLE 4: PREVALENCE OF RESISTANCE *PfDHFR* AND *PfDHPS* GENOTYPES

Genes	Codons	Genotypes	Prevalences
<i>PfDHFR</i>	16	A16	91,37%(n=53/58)
		V16	8,62%(n=5/58)
	51	I51	100% (n=58/58)
		R59	96,55% (n=56/58)
	59	X59	3,44% (n=2/58)
		N108	100%(n=58/58)
<i>PfDHPS</i>	164	I164	100%(n=58/58)
		A436	15,51% (n=9/58)
	436	S436	77,58% (n=45/58)
		A/S436	6,89% (n=4/58)
	437	G437	100%(n=58/58)
E540		53,44%(n=31/58)	
K540		37,93%(n=22/58)	
540	E/K540	8,62%(n=5/58)	
	A613	98,27% (n=57/58)	
	613	S613	1,72% (n=1/58)

High levels of mutation associated with SP resistance was found! In the codon 59 of *PfDHFR*, we found 2 isolates with undescribed genotype, named X59 which gave undescribed profil by previously described PCR-RFLP assay.

TABLE 5: PREVALENCE OF HAPLOTYPES

Genes	Haplotypes	Prevalences % (n)
<i>PfDHFR</i>	V ₁₆ I ₅₁ R ₅₉ N ₁₀₈ I ₁₆₄	12,07 (7/58)
	A ₁₆ I ₅₁ R ₅₉ N ₁₀₈ I ₁₆₄	84,48 (49/58)
	A ₁₆ I ₅₁ X ₅₉ N ₁₀₈ I ₁₆₄	3,45% (2/58)
<i>PfDHPS</i>	S ₄₃₆ G ₄₃₇ E ₅₄₀ A ₆₁₃	37,93% (n=22/58)
	S ₄₃₆ G ₄₃₇ K ₅₄₀ A ₆₁₃	25,86% (n=15/58)
	A ₄₃₆ G ₄₃₇ E ₅₄₀ A ₆₁₃	12,07% (n=7/58)

CONCLUSION:

Data showed the high IPT-SP adhesion is next to 100%. The highest prevalence of genotypes associated with SP drug resistance found call for clinical trials to investigate the efficacy of ITP-SP.

ACKNOWLEDGEMENTS: We thank the Director of Centre Médical de Fougamou; Dr Achille MBIKOU. We thank the pregnant women for their cooperation. We would also like to thank Mme Léa MOUSSOUNDA and Mme Annie Clarisse MAYINDA Ep MOULET for their Technical assistance

1 : Unité d'Evolution, Epidémiologie et Résistances Parasitaires (UNEEREP), Centre International de Recherches Médicales de Franceville (CIRMF) B.P. 769 Franceville Gabon. Phone : 00241 06 25 95 90.

2 : Centre de Recherches Médicales de la Ngounie (CRMN), de Fougamou. B.P. 133 Fougamou, Gabon

3: Département de Parasitologie-Mycologie Médecine Tropicale, Faculté de Médecine, Université des Sciences de la Santé, B.P. 4009 Libreville Gabon. Phone/Fax: 00241 70 48 96.

